What’s next for vaginal ‘rejuvenation’?

August 31, 2018

In late July, the FDA released a safety communication warning against the use of energy-based devices to treat a host of vaginal conditions and symptoms that fall under vaginal “rejuvenation.”  The purpose of the FDA communication was to “Alert patients and healthcare providers that the use of energy-based devices to perform vaginal ‘rejuvenation,’ cosmetic vaginal procedures, or non-surgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function may be associated with serious adverse events. The safety and effectiveness of energy-based devices for treatment of these conditions has not been established.”
The FDA’s focus is on nonsurgical procedures providers perform to treat vaginal laxity; vaginal atrophy, dryness or itchiness; pain during sexual intercourse; pain during urination; decreased sexual sensation; and more. 
Read more at The Aesthetic Channel >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • AmSpa CEO Reflects on the Sonya Dakar Case
    • SkinStylus Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
    • GlossGenius Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Medicare GLP-1 Bridge Program Launches July 1, Expanding Access for Some Patients
    • Universal Healthcare Consulting Becomes Platinum Vendor Affiliate with the American Med Spa Association